Buharalioglu CK, Song CY, Yaghini FA, Ghafoor HU, Motiwala M, Adris T, Estes AM, Malik KU. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.
volves the differentiation, proliferation, and migration of endothelial cells (ECs) and results in tubulogenesis and formation of vessels (13) . ANG II promotes EC proliferation and angiogenesis through the angiotensin type 1 receptor (AT 1 R) (17, 31) .
ANG II also stimulates VEGF synthesis in ECs (6, 23) . The effects of VEGF on ECs are mediated via two receptor tyrosine kinases: VEGR receptor (VEGFR)-1 (Flt-1) and VEGFR-2 (Flk-1/KDR) (8) . VEGF binds with Flt-1 with a 50-fold higher affinity than with Flk-1, although many of the effects of VEGF (e.g., mitogenicity, chemotaxis, and morphological changes) are mediated by its interaction with Flk-1 (22) . However, the angiogenic response to VEGF can be inhibited by selective blockade of the high-affinity receptor Flt-1 alone in vitro and in vivo (3, 12, 27) . The reduction in Flt-1 expression by small interfering (si)RNA inhibits VEGF-induced human umbilical vein EC (HUVEC) proliferation and capillary-like tube formation to a greater extent than that obtained by a reduction in Flk-1 expression (10) . ANG II has been shown to increase Flk-1 mRNA via AT 1 R but has no effect on tube formation and mRNA levels of VEGF and Flt-1 in bovine retinal microcapillary ECs (16) . However, ANG II increased VEGF-induced growth and tube formation (32) . Conversely, in EA.hy926 (EA) cells and human coronary artery ECs (HCAEC), ANG II had no effect on Flk-1 autophosphorylation (32) . Moreover, it has been shown that, in HUVECs, proliferation by ANG II depends on increased expression of VEGF and is abolished by the AT 1 R blocker candesartan or the VEGFR inhibitor Flt-1/Fc (14) . Whether VEGF expressed in ECs mediates tubulogenesis in response to ANG II via Flt-1 or Flk-1 is not known. Moreover, the signaling pathway by which ANG II stimulates angiogenesis through VEGFRs has not been elucidated.
Expression of VEGF and capillary formation from HCAECs in response to ANG II has been reported to be mediated via actin-like scavanger receptor through the activation of NADPH oxidase/ROS and p38 and p44/42 MAPK (16) . In addition to VEGF, other growth factors, including heparin-binding EGF, have been implicated in neovascularization induced by ANG II (12) . However, it is not known whether EGF receptor (EGFR) transactivation in response to ANG II causes angiogenesis via VEGF expression and/or VEGFR activation.
In addition to VEGF and other growth factors, nonreceptor tyrosine kinases, including c-Src, and signal transducers and activators of transcription/JAK have also been implicated in the process of angiogenesis (7) . A nonreceptor tyrosine kinase, spleen tyrosine kinase (Syk), which is ubiquitously distributed in hematopoietic cells, is expressed in ECs and epithelial cells (29) . Syk has been implicated in various EC functions, including morphogenesis, growth, and survival, and contributes to the maintenance of vascular integrity in vivo (17, 39) . Mouse embryos lacking Syk develop abnormal blood-lymphatic endothelial connections (30) . Recently, we (24, 38) have shown that, in VSMCs, ANG II causes the activation of Syk through p38 MAPK-activated c-Src and promotes VSMC hypertrophy and migration. These observations raised the possibility that ANG II might stimulate angiogenesis via EGFR transactivation and VEGF expression and/or Flt-1 or Flk-1 through the activation of Syk. To test this hypothesis, we investigated the effect of Syk and EGFR inhibitors and Syk gene silencing on ANG II-, EGF-, and VEGF-induced capillary tube formation in an in vitro model of ECs, EA cells and HUVECs, and in an ex vivo model of rat aortic ring sprouting. The results of our study show that ANG II promotes tubulogenesis of ECs and aortic sprouting by transactivation of EGFR, which results in the phosphorylation of Flt-1 and activation of Syk independent of VEGF expression. MO) , and EGFR antagonist AG-1478 (Invitrogen, Carlsbad, CA). ANG II, losartan, VEGF, and EGF were dissolved in distilled water to make stock solutions. PD-123319, piceatannol, SU-1498, and AG-1478 were dissolved in DMSO. The final concentration of DMSO was Ͻ0.1% in these experiments.
EXPERIMENTAL PROCEDURES

Materials
Cell culture. HUVEC-derived EA cells (10) were kindly provided by Dr. Cora-Jean S. Edgell (University of North Carolina, Chapel Hill, NC), and HUVECs were purchased from Cell Application (San Diego, CA). EA cells were grown to 90% confluence under 5% CO 2 at 37°C in DMEM (Invitrogen) supplemented with 10% FBS, 1% penicillin-streptomycin, and 0.1% amphotericin B (all from Cellgro Mediatech, Herndon, VA). HUVECs were cultured in medium 199 (M199) supplemented with 20% FBS, 4 U/ml heparin sodium, 2 mM L-glutamine, 15 mM HEPES, and 10 mg/ml EC growth supplement in 0.2% gelatin-coated plates. Rat VSMCs were isolated from SpragueDawley rat thoracic aortae and cultured in M199 with 10% FBS. Cells were made quiescent for 24 h with DMEM or M199 containing 1% FBS before exposure to different agents for all experiments. Experiments were performed according to the protocols approved by our Institutional Animal Care and Use Committee in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. , and the length of tube structures was measured as described in EXPERIMENTAL PROCEDURES (B, bottom). Aortic rings were incubated with DMEM with an intact or denuded endothelium (D). C and E: EA cells and rat aortic rings were exposed to ANG II (0.1, 1, 10, or 100 nM), EGF (1, 3, 10, or 30 ng/ml), VEGF (1, 10, 30, or 50 ng/ml), or their vehicle for 16 h for tube formation and 3-5 days for maximal aortic sprouting. The tube formation from EA cells and aortic sprouting were measured by network formation and sprouting area, respectively, as described in EXPERIMENTAL PROCEDURES. The values for an increase in relative tube formation and aortic sprouting caused by ANG II, EGF, and VEGF were normalized to values obtained with the vehicle (taken as 100%) for tube formation (C, bottom) and aortic sprouting with endothelium (E, bottom), respectively. Values are means Ϯ SE. *Significantly different from that obtained in the presence of vehicle at 0 h (B, C, and E, bottom) (P Ͻ 0.05); †significantly different from that obtained in the presence of vehicle. Magnification: ϫ100. Scale bar ϭ 200 m.
In vitro angiogenesis assay (capillary tube formation). EA cells or
HUVECs were grown in 60-mm tissue culture dishes until 90% confluent and arrested for 24 h. In some experiments, cells were cultured in the presence or absence of different chemicals or neutralizing antibody for the indicated time periods. After trypsinization, cells were counted and resuspended in DMEM for EA cells or M199 for VSMCs and HUVECs containing 1% FBS (at 4 ϫ 10 4 cells/ml) with the indicated concentrations of agonists. Before cells were plated, 48-well tissue culture plates were coated with growth factorreduced Matrigel (0.1 ml/well, BD Biosciences, Bedford, MA), which was allowed to polymerize at 37°C for 30 min, according to the manufacturer's instructions. Cell growth and three-dimensional organization were observed at different time points and photographed with an Olympus CKX41 inverted phase-contrast microscope equipped with an Altra20 CMOS digital camera (Olympus America, Melville, NY). Phase-contrast images were recorded with a video imageanalysis system, Microsuite Five (Olympus America), and network formation was quantified using ImageJ software (National Institutes of Health; http://rsb.info.nih.gov/ij). Results are presented as total tube length as an average of three photographic fields from each well in an experiment. Each experiment was repeated three to four times on different batches of cells.
Ex vivo angiogenesis assay (aortic ring assay). Thoracic aortae were isolated from Sprague-Dawley rats (4 -6 wk old, Charles Rivers, Wilmington, MA) anesthetized with pentobarbital sodium (60 mg/kg ip), cut into 1-mm-thick sections, embedded in 48-well Matrigelcoated plates, and sealed with an overlay of 50 l Matrigel with and without the supplement of agonists as previously described (21) . Inhibitors or neutralizing antibodies were added fresh 30 min before agonists were added. In some experiments, aortic rings were transfected with 20 pmol Syk siRNA (sense: 5=-CACCAUAAAUUUG-CAAGGUC-3= and antisense: 5=-GACCUUGCAAAUUUAUGGUG-3=, Accession No. NM_012758, IDT, Coralville, IA) or its scrambled siRNA (sense: 5=-AAUUUAUGGACGUGGCACUU-3= and antisense: 5=-AAGUGCCACGUCCAUAAAUU-3=) under transfection conditions and then embedded on Matrigel. Transfections were carried out using the manufacturer's protocol with DharmaFECT1 transfection reagent (Dharmacon, Lafayette, CO). The experiments were repeated on at least four aortic rings from different rats, and maximal EC sprouting was observed and photographed as described above in 3-5 days. Four to seven experiments were performed for each series. For quantitative assessment of sprouting, the area of the outer aortic EC sprouting was assessed using ImageJ software.
Western blot analysis. EA cells or HUVECs were lysed in RIPA buffer, and equal amounts of protein were resolved by SDS-PAGE and analyzed by Western blot analysis as previously described (38) . Blots were blocked and incubated with primary antibody (1:500 -1,000) overnight at 4°C. Blots were then exposed to their respective secondary antibodies conjugated with horseradish peroxidase and developed using West Pico chemiluminescent substrate (Pierce Biotechnology, Rockford, IL). The band density was calculated with the ImageJ program. Loading of equal amounts of proteins on gels was confirmed by reprobing the membranes with ␤-actin or corresponding nonphosphorylated antibodies.
Transfection of EA cells and HUVECs with Syk shRNA and its control short hairpin interfering RNA.
The GeneSuppressor (IMG-808) encoding Syk short hairpin interfering (sh)RNA or its control shRNA contained in the plasmid was obtained from Imgenex (San Diego, CA). EA cells and HUVECs were transiently transfected with Syk shRNA or its control shRNA using Effectene transfection reagent (QIAGEN, Valencia, CA) at a ratio of 50 l Effectene to 0.2 g plasmid in DMEM containing 10% FBS for 24 h according to the manufacturer's instructions. Briefly, EA cells and HUVECs were trypsinized, counted, plated at a density of 10 4 cells/cm 2 in six-well plates (MIDSCI, St. Louis, MO) in antibiotic-free DMEM with 10% FBS, and incubated overnight at 37°C with 5% CO2. The next morning, the medium was replaced, and ϳ60 -80% confluent cells were transfected with 0.2 g plasmid of Syk shRNA or control shRNA using 10 l Effectene/well. After 24 h, cell lysates were subjected to Western blot analysis as described above to confirm the silencing effects of Syk shRNA. (Fig. 1A) . The tube-like structures started to appear within 3 h, reached a maximal level at 16 h, and maintained until 24 h (Fig. 1B) . After 24 h, the tube formation declined due to detachment of cells. Exposure of EA cells to lower concentrations of ANG II (0.1-10 nM) for 16 h increased the formation of tube-like structures. The maximum capillary formation occurred at 10 nM ANG II exposure for 16 h (Fig. 1C ). Higher concentrations of ANG II (100 nM) produced only a smaller increase in tube formation, which is consistent with a previous report (19) . Therefore, we chose the maximal proangiogenic concentration of ANG II (10 nM) in subsequent experiments. EGF (1-30 ng/ml) caused tube formation in EA cells at 16 h. Maximal tube formation was observed at 30 ng/ml, which we used in the rest of our experiments (Fig. 1C) . Treatment of ECs with VEGF (1-50 ng/ml) for 16 h also maximally stimulated the formation of capillary-like structures. The maximal effect of VEGF on tube formation was observed at 50 ng/ml, a concentration that we used in the rest of our experiments (Fig. 1C) . We also examined the effect of ANG II (0.1-100 nM), EGF (1-30 ng/ml), and VEGF (1-50 ng/ml) on capillary sprouting from rat aortic rings embedded on Matrigel. Three to five days of incubation of aortic rings with but not without the endothelium resulted in capillary sprouting (Fig. 1D ). Exposure to ANG II (0.1-100 nM), EGF (1-30 ng/ml), or VEGF (1-50 ng/ml) increased aortic capillary sprouting. ANG II at 10 nM, EGF at 30 ng/ml, and VEGF at 50 ng/ml produced maximal effects on aortic sprouting (Fig. 1E) .
ANG II-induced tubulogenesis and rat aortic sprouting are mediated through Flt-1 but not Flk-1. To determine the subtype of VEGFR involved in ANG II-, EGF-, and VEGFinduced angiogenesis, we examined the effect of Flt-1 neutralizing antibody, Flt-1/Fc, and a selective Flk-1 tyrosine kinase inhibitor, SU-1498, on ANG II-, EGF-, and VEGF-induced tube formation in EA cells and rat aortic sprouting. Flt-1/Fc, but not SU-1498 (10 M), inhibited the effect of ANG II, EGF, and VEGF on capillary tube formation and aortic sprouting, respectively (Fig. 2, A and B) . A higher concentration of SU-1498 (25 M) inhibited VEGF-but not ANG II-and EGF-induced tube formation ( Fig. 2A ). These observations indicate that ANG II-and EGF-induced angiogenesis is mediated via Flt-1 but not Flk-1, whereas VEGF stimulates angiogenesis through both Flt-1 and Flk-1. (9, 16) . To determine whether the ANG II-induced process of angiogenesis is mediated via VEGF expression, we examined the effect of ANG II on VEGF expression in the presence of Flt-1/Fc and SU-1498 and their vehicle. ANG II initiated an increase in VEGF expression after 1 h, which became more prominent at 16 h, in EA cells (Fig. 3A) . This effect of ANG II was not altered by either Flt-1/Fc or SU-1498 (Fig. 3, B and C, respectively) ) (data not shown), within 10 min, which was maximal at 4 and 1 h, respectively, and was maintained at a lower level at 16 h (Fig. 4, A and B, respectively) . VEGF increased Flt-1 phosphorylation within 10 min, which was maximal at 30 min, and was maintained at a somewhat lower level for the course of the experiment up to 16 h (Fig. 4C) . The phosphorylation of Flk-1 by VEGF was also maximal at 30 min and was maintained to a lower level for 1 h (Fig. 4C) . Phosphorylation of Flt-1 caused by ANG II and EGF was inhibited by Flt-1/Fc but not by SU-1498, an Flk-1 antagonist. VEGF-induced phosphorylation of Flt-1, but not Flk-1, was blocked by Flt-1/Fc, whereas phosphorylation of Flk-1, but not Flt-1, was inhibited by SU-1498, an Flk-1 blocker in EA cells (Fig. 4, D-F) . These results indicate that ANG II and EGF selectively stimulate Flt-1 but not Flk-1 phosphorylation, whereas VEGF causes the phosphorylation of both Flt-1 and Flk. Experiments on the effect of ANG II, EGF, and VEGF on the phosphorylation of VEGFRs and other signaling molecules to be described were not performed in aortic rings because of the heterogeneity of cells in the intact tissue.
ANG II-induced VEGF expression is not mediated via Flt-1 or Flk-1 in EA cells. ANG II is known to stimulate VEGF expression in ECs
ANG II-induced tubulogenesis and rat aortic sprouting caused by Flt-1 activation are mediated via EGFR transactivation. ANG II is known to produce its effect on VSMC migration and proliferation through the transactivation of EGFR (5, 35) , and heparinbinding EGF has been implicated in neovascularization induced by ANG II (2) . Therefore, we investigated the effect of the EGFR blocker AG-1478 on ANG II-, EGF-, and VEGFinduced tube formation and aortic sprouting and phosphorylation of EGFR and VEGFRs in EA cells. AG-1478 (200 nM) inhibited ANG II-and EGF-but not VEGF-induced tube formation and aortic sprouting (Fig. 5, A and B) . It also blocked ANG II-and EGF-induced phosphorylation of EGFR and Flt-1 (Fig. 5, C and D) . VEGF did not stimulate the phosphorylation of EGFR, and phosphorylation of Flt-1 and Flk-1 caused by VEGF was not altered by AG-1478 (data not shown). ANG II did not cause associations of EGFR and Flt-1, Flt-1 and Syk, Flt-1 and Syk, or VEGFR and Flt-1 in response to VEGF, as determined by coimmunoprecipitation of these molecules (data not shown).
Piceatannol and Syk shRNA inhibit ANG II-, EGF-, and VEGF-induced tubulogenesis and Syk phosphorylation in EA cells and rat aortic ring sprouting.
To investigate the contribution of Syk to ANG II-, EGF-, and VEGF-stimulated tube formation from EA cells and aortic sprouting, we examined the effect of these agents on Syk activation by following its phosphorylation and modulation by ANG II receptor and Flt-1 and Flk-1 blockers. Moreover, we examined the effect of Syk inhibitors on tube formation from EA cells and aortic sprouting. We used the Syk inhibitor piceatannol (31) and Syk shRNA plasmid designed against the human sequence for experiments in EA cells and siRNA Syk designed against the rat sequence for experiments in aortic rings. ANG II (10 nM), EGF (30 ng/ml), and VEGF (50 ng/ml) increased maximal Syk phosphorylation within 10 -30 min (Fig. 6, A-C, respectively) . ANG II-induced Syk phosphorylation in these cells was inhibited by AT 1 R (losartan) but not AT 2 R (PD-123319) blocker (Fig. 6D) . ANG II receptor blockers did not alter EGF-or VEGF-induced Syk phosphorylation in EA cells (Fig. 6, E and  F) . ANG II-, EGF-, and VEGF-induced tube formation from EA cells and aortic sprouting was inhibited by piceatannol (5 M; Fig. 7, A and B, respectively) . ANG II-, EGF-, and VEGF-induced Syk phosphorylation but not Flt-1 in EA cells was inhibited by piceatannol (Fig. 7, C-E) . The effect of ANG II, EGF, and VEGF to stimulate tube formation in EA cells and aortic sprouting in aortic rings was abolished after transient transfection with Syk shRNA but not its control shRNA and by Syk siRNA but not its scrambled siRNA, respectively (Fig. 8,  A and B) . Transient transfection of EA cells with Syk shRNA but not its control shRNA reduced Syk protein levels and ANG II-, EGF-, and VEGF-induced Flt-1 phosphorylation (Fig. 8,  C-E) . Syk phosphorylation elicited by ANG II, EGF, and VEGF was blocked by Flt-1/Fc but not by the Flk-1 blocker SU-1498 at 10 M (Fig. 9, A-C , and some of our colleagues questioned if the signaling pathway described for the ANG II-induced process of angiogenesis also occurs in HUVECs that are derived from EA cells. Therefore, we conducted several of the above experiments in HUVECs. ANG II-, EGF-, and VEGF-induced tube formation and Flt-1 phosphorylation were inhibited by Flt-1/Fc but not by SU-1498 (Fig. 10, A-D) , and VEGFinduced Flk-1 phosphorylation was inhibited by SU-1498 in these cells (Fig. 10E) . ANG II-and EGF-induced tube formation and EGFR and Flt-1 phosphorylation were inhibited by AG-1478 in HUVECs. AG-1478 did not alter VEGF-induced tube formation and Flt-1 phosphorylation, and VEGF did not affect EGFR phosphorylation (Fig. 11) . ANG II-, EGF-, and VEGF-induced tube formation and Syk but not Flt-1 phosphorylation were inhibited by the Syk inhibitor piceatannol in HUVECs (Fig. 12, A-D) . Syk shRNA but not control shRNA inhibited ANG II-, EGF-, and VEGF-induced tube formation but not Flt-1 phosphorylation in these cells (Fig. 12, E-H) . ANG II-and EGF-induced Syk phosphorylation were inhibited by Flt-1/Fc and AG-1478 but not by SU-1498. VEGF-induced Syk phosphorylation was inhibited by Flt-1/Fc but not by SU-1498 and AG-1478 (Fig.  13) . ANG II-induced tube formation and Syk phosphorylation in HUVECs were inhibited by AT 1 R (losartan) but not AT 2 R (PD-123319) blocker (data not shown). Fig. 8 . Syk short hairpin interfering (sh)RNA and Syk small interfering (si)RNA inhibit ANG II-, EGF-, and VEGF-induced tube formation and aortic sprouting, respectively. A and B: quiescent EA cells transfected with human Syk shRNA, its control shRNA, or vehicle and rat aortic rings transfected with rat Syk siRNA, its scrambled (SCR) control, or vehicle were then exposed to ANG II (10 nM), EGF (30 ng/ml), VEGF (50 ng/ml), or their vehicle for 16 h for tube formation (A) and 3-5 days for maximal rat aortic sprouting (B). The value of increase in tube formation and aortic sprouting obtained in the presence of the vehicle of ANG II, EGF, or VEGF was taken as 100% for angiogenesis assays. C-E: EA cells were transfected with human Syk shRNA, its control shRNA, or vehicle and exposed to ANG II (10 nM), EGF (30 ng/ml), VEGF (50 ng/ml) (ϩ), or their vehicle (Ϫ) for 30 min. Cells were lysed and subjected to SDS-PAGE and Western blot analysis, and blots were then probed with anti-p-Flt-1, anti-Flt-1, and anti-Syk antibodies. Bands were detected, and the density of bands was measured as described in EXPERIMENTAL PROCEDURES. Blots are representative of three to four experiments (C-E, top). The density of p-Flt bands was normalized to the quantity of Flt-1 and presented as the fold increase from the corresponding value obtained in the presence of the vehicle, which was taken as 1. Values are means Ϯ SE. *Significantly different from the corresponding value obtained in the presence of the vehicle of ANG II, EGF, or VEGF; †significantly different from the corresponding value obtained in the presence of the vehicle of Syk shRNA (C-E, bottom) (P Ͻ 0.05).
DISCUSSION
This study demonstrates that ANG II promotes the process of angiogenesis via EGFR transactivation, resulting in the phosphorylation of Flt-1 and Syk activation independent of VEGF expression. ANG II in low concentrations (10 nM) stimulates the process of angiogenesis, as shown by increased EC proliferation and capillary tube formation from vascular ECs in vitro and ex vivo capillary sprouting from aortic rings via AT 1 R (2, 19, 28) . ANG II stimulates VEGF expression in ECs (9, 16) , and ANG II-induced HCAEC proliferation is inhibited by VEGF neutralizing antibody against Flt-1 (14) . In the present study, we confirmed that ANG II-induced tube formation from EA cells and HUVECs and capillary sprouting from rat aortic rings are blocked by AT 1 R (losartan) but not AT 2 R (PD-123319) blocker (data not shown). Our finding that ANG II-, EGF-, and VEGF-induced tube formation from EA cells and HUVECs and aortic sprouting were inhibited by Flt-1 neutralizing antibody Flt-1/Fc, but not by Flk-1 blocker SU-1498, suggest that these effects of ANG II, EGF, and VEGF are mediated via the activation of Flt-1. Since SU-1498 at higher concentrations (25 M) inhibited VEGF-but not ANG II-and EGFR-induced tube formation from EA cells, it appears that VEGF stimulates tube formation also via Flk-1. ANG II also stimulates VEGF expression, and VEGF has been reported to stimulate angiogenesis mainly through Flt-1 (8) . This suggests that VEGF might mediate ANG II-induced angiogenesis. In our study, ANG II also increased VEGF expression and caused the phosphorylation of Flt-1 but not Flk-1. Although we cannot exclude the involvement of VEGF in ANG II-induced tube formation from EA cells, it appears to be unlikely for the following reasons. First, in these cells, ANG II caused the phosphorylation of Flt-1 within 5 min, which reached a maximum at 4 h, whereas the expression of VEGF was slightly increased at 1 h and reached a maximum at 16 h. Second, ANG II caused the phosphorylation of Flt-1 but not Flk-1, whereas VEGF caused the phosphorylation of both Flt-1 and Flk-1. Finally, ANG II in high concentrations (100 nM) also increased VEGF expression in EA cells (data not shown), but its effect on tube formation was less than that at 10 nM.
ANG II stimulates the proliferation and migration of VSMC through EGFR transactivation (24) , and heparin-binding EGF has been shown to be involved in neovascularization induced by ANG II (12) . Our data showed that 1) EGF increases tubulogenesis from EA cells and HUVECs and aortic sprouting, 2) EGF and ANG II stimulated EGFR phosphorylation in EA cells and HUVECs, and 3) these effects of EGF and ANG II were inhibited by the EGFR blocker AG-1478, suggesting that ANG II-induced tubulogenesis and aortic sprouting are mediated through EGFR transactivation. Because 1) EGFinduced tubulogenesis from EA cells and HUVECs and aortic sprouting were blocked by VEGF neutralizing antibody Flt-1/Fc but not by the Flk-1 antagonist SU-1498; 2) EGF increased the phosphorylation of Flt-1 but not Flk-1, and it was inhibited by Flt-1/Fc but not SU-1498; and 3) VEGF-induced tubulogenesis and aortic sprouting as well as phosphorylation of Flt-1 and Flk-1 were not blocked by the EGFR blocker AG-1478, it appears that ANG II stimulates angiogenesis via EGFR transactivation by the phosphorylation of Flt-1 independent of VEGF expression.
To further elucidate the mechanism by which ANG II via EGFR transactivation stimulates the process of angiogenesis, we investigated the role of Syk, which is expressed in ECs and is involved in the morphogenesis, growth, and survival of ECs and contributes to the maintenance of vascular integrity in vivo (17, 39) . Our findings that 1) ANG II, EGF, and VEGF increased Syk phosphorylation; 2) ANG II-but not EGF-and VEGF-induced Syk phosphorylation was blocked by AT 1 R (losartan) but not AT 2 R (PD-123319) blocker; and 3) the Syk inhibitor piceatannol blocked ANG II-, EGF-, and VEGFinduced tube formation and Syk phosphorylation in EA cells and HUVECs as well as capillary sprouting from aortic rings suggest that Syk mediates ANG II-induced angiogenesis. Further supporting this conclusion was our demonstration that transfection of EA cells with human Syk shRNA but not its control shRNA reduced tube formation and phosphorylation of Syk in EA cells and HUVECs, and transfection of aortic rings with rat Syk siRNA inhibited capillary sprouting in response to ANG II. Because 1) the Syk inhibitor piceatannol and Syk shRNA also blocked EGF-and VEGF-induced tubulogenesis and phosphorylation of Syk in EA cells and HUVECs; 2) piceatannol and Syk siRNA inhibited capillary sprouting of aortic rings stimulated by EGF and VEGF; 3) ANG II-induced Syk phosphorylation in EA cells and HUVECs was inhibited by AT 1 R (losartan) but not AT 2 R (PD-123319) blocker; 4) Flt-1/Fc but not SU-1498 blocked ANG II-, EGF-, and VEGF-induced Syk phosphorylation in EA cells and HUVECs; 5) piceatannol or Syk shRNA did not alter EGF-and VEGF-induced phosphorylation of EGFR and Flt-1 as well as Flt-1 and Flk-1, respectively, in EA cells and HUVECs; and 6) VEGF-induced Syk phosphorylation in EA cells and HUVECs was not altered by the EGFR blocker AG-1478, it appears that the ANG II-induced process of angiogenesis is mediated via AT 1 R through EGFR transactivation, which promotes the phosphorylation of Flt-1 and activation of Syk. We (29) have previously reported that the effect of ANG II to stimulate VSMC proliferation is mediated via EGFR transactivation independent of Syk activation, whereas protein synthesis is mediated via Syk independent of EGFR transactivation. Therefore, it appears that distinct signaling mechanisms are involved in Syk-dependent ANG II-induced protein synthesis in VSMCs and tubulogenesis in ECs.
ANG II did not stimulate associations of EGFR with Flt-1 or Flt-1 with Syk, as determined by coimmunoprecipitation experiments, suggesting that neither EGFR nor Syk interact with 
B-E:
HUVECs were preincubated with Flt-1 neutralizing antibody (Flt-1/Fc, 5 g/ml), Flk-1 tyrosine kinase inhibitor SU-1498 (10 M), or their vehicle for 30 min and then exposed to ANG II (10 nM), EGF (30 ng/ml), VEGF (50 ng/ml) (ϩ), or their vehicle (Ϫ). Cells were lysed and subjected to SDS-PAGE and Western blot analysis, and blots were probed with anti-p-Flt-1, anti-Flt-1, anti-Flt-1, and anti-Flk-1 antibodies. Bands were detected, and the density of bands was measured as described in EXPERIMENTAL PROCEDURES. Blots are representative of three to four experiments. Densities of p-Flt-1 and p-Flk-1 bands were normalized to the quantities of Flt-1 and Flk-1, respectively, and presented as fold increases from the value obtained at time 0, which was taken as 1. *Significantly different from that obtained in the presence of the vehicle of ANG II, EGF, or VEGF; †significantly different from the corresponding value obtained in the presence of the vehicle of Flt-1/Fc (P Ͻ 0.05).
or stimulate directly Flt-1, and other signaling molecules, including p38 MAPK, p44/42 MAPK, and PKC-␦, might be involved in the activation of Flt-1 by EGFR and/or of Syk by Flt-1. p38 MAPK is known to mediate transactivation of EGFR and EGFR activation, resulting in the activation of p38 MAPK and p44/42 MAPK in VSMCs (24) , and both kinases have been shown to be involved in the process of angiogenesis (19) . ANG II is also known to cause the activation of PKC isotypes, including PKC-␦, in VSMCs (25) , and PKC-␦ has been reported to mediate thrombin-induced ICAM-1 expression by increasing the transcriptional capacity of NF-B via activation of Syk in HUVECs (4). Whether ANG II-induced activation of Syk by Flt-1 receptor and angiogenesis are mediated by PKC-␦ or other isotypes of PKC (37) implicated in angiogenesis remains to be determined. Moreover, further studies are required to determine the relationship of VEGF-induced Flk-1 phosphorylation and the signaling mechanism of tube formation via Flk-1 by VEGF that is independent of Syk activation.
In conclusion, our study demonstrates (Fig. 14) that ANG II stimulates the process of angiogenesis, tube formation from EA cells and HUVECs, and capillary sprouting from rat aortic rings via transactivation of EGFR, which, in turn, promotes the phosphorylation of Flt-1, resulting in the activation of Syk, most likely independent of VEGF expression (ANG II ¡ EGFR ¡ Flt-1 ¡ Syk). 12 . ANG II-, EGF-, and VEGF-induced tube formation from HUVECs is inhibited by piceatannol. Quiescent HUVECs were treated with the Syk inhibitor piceatannol (5 M) or its vehicle for 30 min (A-D) or were transfected with human Syk shRNA, its control shRNA, or vehicle (E-H) and then exposed to ANG II (10 nM), EGF (30 ng/ml), VEGF (50 ng/ml), or their vehicles for 16 h for tube formation, or cells were lysed and subjected to SDS-PAGE for Western blot analysis. The value obtained in the presence of the vehicle of ANG II, EGF, or VEGF was taken as 100% for angiogenesis assays (A and E). Blots were probed for p-Flt-1, Flt-1, p-Syk, and Syk. Bands were detected, and the density of bands was measured as described in EXPERIMENTAL PROCEDURES. Blots are representative of three to four experiments. Densities of p-Flt-1 and p-Syk bands were normalized to the quantities of Flt-1 or Syk, respectively, and presented as folds increase from the corresponding value obtained in the presence of the vehicle, which was taken as 1.00. Values are means Ϯ SE. *Significantly different from the corresponding values obtained in the presence of the vehicle of ANG II, EGF, or VEGF; †significantly different from the presence of the vehicle of piceatannol (B-D) or in the presence of the vehicle of Syk shRNA (F-H) (P Ͻ 0.05). 
